Hikma to launch 4 generics in Canada

The launches represent the first or second generic versions on the Canadian market and treat conditions across various therapeutic areas.
Sandra Levy
Senior Editor
Sandra Levy profile picture

Hikma is set to introduce four new sterile injectable medications in Canada.

All of the medications, which will launch soon, represent the first or second generic versions on the Canadian market and will treat conditions across various therapeutic areas.

[Read more: Hikma to acquire Custopharm]

The products launches include:

  • Dantrolene sodium for injection, 20 mg vial
  • Micafungin sodium for injection, 50 mg vial, 100 mg vial
  • Mitomycin for injection, 20 mg vial
  • Progesterone injection, 50 mg/ml, 10 ml vial

With these launches, Hikma now markets approximately 30 different sterile injectable medicines in Canada, with plans to launch up to 13 additional sterile injectable products in the country this year.

“Since expanding into Canada last year through the acquisition of Teligent’s Canadian injectable assets, we have been working hard to strengthen relationships with customers and Health Canada, while setting the stage to introduce Hikma’s leading sterile injectables portfolio into the country,” said Mike Armstrong, Canada Country director, Hikma. “The launch of these new sterile injectable medicines is a significant step forward in growing our business in Canada and provides important new treatment options for patients and health care providers.”

[Read more: Hikma intros Kloxxado]

“The expansion of our sterile injectable business in Canada continues the strong momentum of our injectables business globally and builds on our position as a leading supplier of injectable medicines to U.S. hospitals with a reputation for quality and reliability,” said Riad Mishlawi, president of injectables at Hikma. “We look forward to offering Canadian hospitals critical injectable drugs for their patients’ needs and furthering our impact as a growing player in this important market.”